Understanding Diabetic retinopathy and diabetic macular edema
Diabetic retinopathy affects the retina’s small vessels and associated retinal tissue. Early nonproliferative changes can be visible to an examiner while reading and distance vision still seem normal. Proliferative retinopathy means abnormal new vessels have developed; it is a different stage from simply having a high glucose reading. [1] [3]
Diabetic macular edema, or DME, is fluid-related thickening of the macula, the retinal area used for detailed central tasks. DME can occur at different retinopathy stages. A useful report therefore describes both the retinopathy stage and whether swelling involves the center and affects vision; one label does not answer all three questions. [2] [3]
One condition. Different experiences.
Explore different selected symptom features, then read how they may vary. These examples are not stages or a clinical test.
Original VisualSim schematic illustrations, informed by the cited clinical descriptions. These are not study figures, patient recordings or validated severity levels.
No obvious change
An apparently clear scene does not exclude retinopathy. Screening is intended to find changes before symptoms become a reliable warning, so matching a simulated picture cannot replace the examination. [1] [7]
Central detail becomes harder
Macular swelling can make small print, faces or fine work less clear. Wavy detail and reduced contrast may matter even when a large, high-contrast eye-chart letter can still be read. [2] [8]
Floaters or obscured vision
Bleeding into the vitreous can appear as spots, cobwebs or a haze. The pattern and amount vary; a moving-floater example is only one possible experience, not a measure of retinopathy severity. [1] [2]
Two related questions in diabetic retinal disease
Original educational schematic; retinopathy stage and macular edema are related but different findings. [2] [3]
Original VisualSim teaching diagram · © VisualSim. Clinical basis in linked sources; not a published study figure. Image provenance.- Vessel changes
Examination identifies leakage, bleeding and abnormal vessel growth.
- Macular involvement
OCT helps determine whether the central retina is swollen.
- Function and plan
Symptoms, acuity and follow-up needs inform the treatment discussion.
What is happening—and what remains uncertain
Damage to small retinal vessels can produce leakage and areas receiving inadequate blood supply. Leakage near the macula can disturb the arrangement of retinal tissue needed for sharp central vision. Imaging and function are related, but a thicker OCT scan does not by itself tell exactly how a person reads or sees contrast. [2] [4] [8]
In proliferative disease, abnormal vessels can grow in response to retinal ischemia. These vessels may bleed, and associated scar tissue can pull on the retina. Treatments aimed at leakage, abnormal vessel growth and mechanical traction address different processes; they should not be presented as interchangeable ways to remove all retinal damage. [2] [3]
What can look similar?
Retinopathy versus macular edema
Retinopathy describes the wider diabetic retinal disease; edema describes swelling. Good central acuity can coexist with center-involved DME, while proliferative disease can threaten vision through mechanisms beyond macular swelling. [3] [5]
Similar-looking symptoms can have different causes. A matching picture cannot establish a diagnosis.
What an assessment may involve
- Screening and comprehensive examinationRetinal photography can support screening and referral. Dilated examination assesses the retinal disease and other eye structures; an unclear screening photograph or an abnormal result needs an appropriate follow-up pathway, not reassurance from symptoms alone. [3] [7]
- OCT and selected vessel imagingOCT shows retinal layers and fluid near the macula. Fluorescein angiography may clarify leakage or circulation when clinically useful. Ask what each test changes about the plan rather than treating every scan as mandatory at every visit. [2] [7]
- A follow-up plan for your stageThe interval depends on diabetes type, previous findings, progression and other circumstances such as pregnancy. Ask who communicates the result and books the next visit; screening invitations and a retina-treatment schedule serve different purposes. [3] [7]
What may help—and what is still being studied
Diabetes and vascular care remain important
Glucose, blood-pressure and lipid management are part of reducing retinal risk. Coordinate with the diabetes team when major treatment changes are planned; this guide cannot set personal targets or justify stopping a prescribed medicine. [3] [6]
Treating macular edema
Anti-VEGF injections are a common treatment for center-involved DME that impairs vision. Selected eyes with good acuity may instead begin with closely monitored observation. That approach requires examinations and access to rescue treatment if vision worsens; it does not mean ignoring swelling. [3] [5]
Treating proliferative disease
Panretinal laser and anti-VEGF treatment are both established options in appropriate eyes. Visit reliability, costs and competing eye findings matter. Surgery may be considered for complications such as persistent vitreous bleeding or traction; a treatment recommendation should explain which problem it addresses. [2] [4]
What this can mean for daily life
Make diabetes information readable
Ask for accessible medication labels, glucose-device settings and instructions if central detail is reduced. A diabetes educator and sight-loss service can help make the diabetes routine usable rather than relying on increasingly small print. [6] [7] [9]
Adapt reading and screens
Try adjustable text size, stronger contrast and lighting suited to the task. Vision rehabilitation can help choose tools around actual reading, cooking and work difficulties; support is relevant before vision is completely lost. [9]
Bring a clearer description to your appointment
Choose the questions you want to discuss. These choices stay in this page’s memory.
Research, with the context left in
Selected studies and guidance, with their populations and limitations. These are curated educational summaries, not a complete systematic review or a formal evidence rating.
Protocol S: five-year ranibizumab versus panretinal laser
Mean acuity among five-year completers was approximately 20/25 in both arms. Ranibizumab had less field loss and less vision-impairing DME, with continuing injection requirements. [4]
Limits and applicability: Only 66% of surviving eligible participants completed five years. Attrition, small field-test subsets and substantial treatment overlap limit claims of universal superiority or results without reliable follow-up.
Protocol V: center-involved DME with good acuity
At two years, the groups did not differ significantly in the primary vision-loss outcome. About one-third of the observation group received rescue injections. [5]
Limits and applicability: Applies to the trial’s good-acuity population with structured monitoring and rescue access, not untreated vision-impairing DME or loss to follow-up.
Protocol T: comparing three anti-VEGF strategies
All groups improved on average. Relative differences depended on starting acuity; aflibercept retained an advantage over bevacizumab in the poorer-acuity subgroup at two years, without the same clear advantage over ranibizumab. [10]
Limits and applicability: Protocol-directed retreatment, selected eligibility and subgroup interpretation limit a blanket drug ranking; results do not describe every newer formulation or individual response.
Questions researchers still need to answer
- Which monitoring schedules best preserve vision when transport, cost or health problems interrupt visits?
- How should low-contrast and reading outcomes complement OCT thickness and high-contrast acuity?
- Which patients with good-acuity DME benefit from earlier treatment rather than monitored rescue?
Trusted places to go next
Selected clinical references, research, practical support and ways to connect. Official pages checked 24 October 2026; each entry explains its scope and region.
American Diabetes Association: eye health
Diabetes-focused eye information and routes to broader diabetes support; education does not replace a retinal assessment.
Diabetes UK: retinopathy information and support
Explains screening, diabetic eye changes and routes to the charity’s diabetes support services.
RNIB: diabetes-related eye conditions
Accessible information and routes to practical sight-loss support, including help adapting daily tasks.
Connections listed by the organization.
ASRS: diabetic retinopathy
Retina-specialist patient information explaining retinal findings and treatment categories.
Questions you may still have
Can I have retinopathy with clear vision?
Yes. Early changes may be detectable before you notice them; the screening result and examination are more informative than a simulation match. [1] [7]
Does every OCT showing DME require immediate injections?
No. Starting acuity, center involvement and other findings matter. Protocol V supports monitored observation for selected good-acuity eyes with rescue treatment available, not self-directed waiting. [3] [5]
Sources, image credits and review status
Compiled by VisualSim from clinical references and published research. Sources checked 24 October 2026. Independent clinical review has not been recorded; no named clinical reviewer or clinical validation is claimed. Research evidence and its limitations are linked below.
- National Eye Institute: Diabetic retinopathy (n.d.; institution).
Patient-facing symptoms, complications and examination scope read; source-check date is not a clinical review date.
Checked 2026-10-24 · Public page checked - ASRS: Diabetic retinopathy (n.d.; institution).
Retina-specific mechanisms, imaging and care categories checked; no individual prognosis inferred.
Checked 2026-10-24 · Public page checked - ADA: Retinopathy, Neuropathy, and Foot Care — Standards of Care in Diabetes 2026 (2026; guideline).
Current retinopathy recommendations checked through the PMC version; publisher direct fetch was unavailable. No personal target or drug dose reproduced.
Checked 2026-10-24 · Full text checked - Gross et al.: Five-year outcomes of panretinal photocoagulation versus ranibizumab for proliferative diabetic retinopathy (2018; trial).
Design, five-year attrition, acuity and secondary outcomes read from indexed abstract; supplement not independently audited.
Checked 2026-10-24 · Abstract/indexed material checked; complete full-text review not claimed - Baker et al.: Initial aflibercept, laser or observation for DME with good visual acuity (2019; trial).
Eligibility, rescue-treatment strategy and primary two-year result checked; observation was active monitored care.
Checked 2026-10-24 · Full text checked - American Diabetes Association: Eye health (n.d.; institution).
Public education and organization scope verified; United States services not assumed globally available.
Checked 2026-10-24 · Public page checked - Diabetes UK: Diabetic retinopathy and eye problems (n.d.; institution).
Resolved canonical page read for symptoms, screening context and practical support.
Checked 2026-10-24 · Public page checked - DRCR Retina Network: Low-contrast acuity ancillary study within Protocol V (2021; trial).
Ancillary-study scope checked; not counted as an independent randomized cohort or proof of benefit on every contrast task.
Checked 2026-10-24 · Abstract/indexed material checked; complete full-text review not claimed - RNIB: Diabetes-related eye conditions (n.d.; institution).
Public condition information and sight-loss support routes read; service eligibility not assumed outside the UK.
Checked 2026-10-24 · Public page checked - DRCR.net: Aflibercept, bevacizumab or ranibizumab for DME — two-year Protocol T results (2016; trial).
Indexed trial abstract and linked PMC result text checked; some direct client requests returned an empty footer. No full-text access claim made.
Checked 2026-10-24 · Abstract/indexed material checked; complete full-text review not claimed - NEI — Retinal detachment: emergency warning signs (n.d.; institution).
New flashes, many new floaters or a curtain/shadow warrant eye-doctor or emergency-department assessment right away; general warning-sign guidance, not a diagnosis.
Checked 2026-10-24 · Public page checked - NHS — Vision loss: immediate and urgent action (n.d.; institution).
Immediate-action section checked for sudden inability to see or sudden severe eye pain; ordinary blur has a separate urgent route. Emergency numbers are UK-specific.
Checked 2026-10-24 · Public page checked
The simulator helps people communicate an experience. It cannot diagnose a condition, measure a visual field, or establish that someone is safe to drive.